



25th Edition

European Pharma and Biotech Project, Program and Portfolio Management Conference



Event Location
London
United Kingdom



Event Dates
March 7-8 | 2024

Gold Sponsors



Intelligencia AI


Planisware

Silver Sponsor



Grey Swan

2024 PPM Summits Worldwide



World's Greatest PHARMA, BIOTECH & HEALTHCARE
Project and Portfolio Management Conferences
UNITED under WHY Summits PPM WORLD TOUR

What to expect?



2 day-long conference filled with the TOP industry speakers



Workshops and Roundtables for a deeper dive into important topics in the MedTech industry now



Sharing new ideas and building strong connections



Fun and icebreaking social events every evening with delegates, speakers and sponsors of the event



Interesting Keynotes, Case Studies and Panel Discussions



Creative and inspiring platform for fruitful discussion



The friendly and highly stimulating atmosphere in a smaller circle (around 150 attendees per conference)

Key Topics

- LEVERAGING TECHNOLOGIES FOR IMPROVED DECISION MAKING
 - DECIDING ON THE RIGHT MIX OF THERAPEUTIC AREAS
 - DECISION ANALYSIS AND STRUCTURED DECISION MAKING
 - ASSESSING PORTFOLIO RISK AND RETURN UNDER MULTIPLE FUTURE SCENARIO PREDICTIONS
 - GOVERNANCE AND RISK MANAGEMENT
 - DEEP DIVE INTO ARTIFICIAL INTELLIGENCE (AI), MACHINE LEARNING, AND PREDICTIVE ANALYTICS TO IMPROVE DECISION-MAKING
 - ALIGNING PROJECT AND PROGRAM EXECUTION TO CORPORATE STRATEGY
 - CAPACITY PLANNING IN A RESOURCE-CONSTRAINED ENVIRONMENT
- ... and more!



Reasons to attend



Friendly and highly stimulating atmosphere in a smaller circle (around 150 attendees per conference)



Fun icebreaking social events every evening with delegates, speakers and sponsors of the event.



Creative and inspiring platform for fruitful discussion



Workshops and Roundtables for a deeper dive into important topics in the Pharma industry now



Sharing new ideas and building strong connections



Big & SME Pharma and Biotech companies

20+
LEADING
SPEAKERS

20+
CASE STUDIES,
PRESENTATIONS,
AND PANELS

2
DAYS

1
MASTERCLASS

8+
HOURS OF
NETWORKING



"An event where everyone could participate in the conversation. Great mix of Panel discussion, round table and presentations that give the ability to network and meet everyone in the room."



Kelly Keen
Global Project & Portfolio Manager

Same-venue Masterclass!

Learn how to quantify and manage risk at project, program, and portfolio levels. Assess the extent to which multiple indications and/or lines of therapy affect program risk and valuation. Quantify the likelihood that your R&D pipeline portfolio and commercial portfolio will meet annual corporate targets.

Project, Program, and Portfolio Risk Analysis Masterclass

January 23-24

★ This masterclass is held at the same venue and is led by Dr. Richard Bayney, a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development.

Audience



This Masterclass is particularly interesting for industry professionals across Pharma, Biotech, Medical Devices, and Consumer Care involved in:



LEARN MORE & REGISTER

Scan the QR code or visit www.whysummits.com/dapmlondon to learn more!

Key Topics



- Quantification of project risk using risk decomposition and Decision Trees
- Quantification of program risk using correlated project risks and Decision Trees
- Quantification of portfolio risk using simulation
- Generation of strategic alternatives for Clinical Development, Registration, and Commercialization
- Selecting dominant strategies based on eNPV
- Accounting for commercial uncertainty in the product portfolio using simulation
- Accounting for risk and commercial uncertainty in the pipeline portfolio
- Quantifying the likelihood of meeting corporate growth targets (Long Range Plan)



Testimonials



„I really enjoy Why Summits' conference because as a senior project manager it's been really helpful to see the ideas and exchange them with the other people in the industry.“

David Rose

Senior Project Manager, CAI



“I had the pleasure of attending Why Summit's 18th American Pharma & Biotech PPM conference. I left with fresh ideas, tools, and new friends in my network to collaborate with and further grow. I encourage all of you to take time out of your day to day and invest in you.“

Brittany Hall

Director, PM Community of Practice,
Thermo Fisher Scientific, USA



One of the things I really like about Why Summits is how intimate the conference is. You know there are a lots of other places that you can go to do talk about project management and portfolio management which I really love, you know a large global meetings like DIA, NF BIO, but there's nothing like the intimacy that Why Summits provides to us and being able to network with the small group of people. So that's one of the many reasons why I choose Why Summits

Ailsa Mendez

Executive Director Biotech Portfolio Lead, PPD

Thanks so much for organizing and for the super talented speakers! Fantastic event“

Alejandro Martorell Riera

Senior Project Manager, Kite Pharma, USA



Why Summits brings together some of the most respected thought leaders in Portfolio Management in the BioPharma industry. Whether you're a novice or seasoned leader in this discipline, there are always nuggets to be found in a presentation, panel, or roundtable discussion. If you're striving to build or improve your capabilities in Portfolio Management, the Why Summits events are the places to be.

Richard Bayney

President & Founder, Portfolio
Manager & Decision Analyst, PPVC



This conference has really surprised us, how kind everyone was. I feel like everyone was so open to connecting. It was like we were already all a big group of friends coming together.“

Stephen McKay Clark

Global Solution Lead, Proggio

Elena Aparicio Becerra

Innovation Project Manager, Green Transition



“A great event with many open-minded (non-competing) participants that are willing to share their thoughts openly on many different, highly relevant topics.“



Andreas Norlin

COO
VAR2 Pharmaceuticals

Our Sponsors





Dear Colleague,

Navigating the complex world of pharma R&D requires exceptional portfolio prioritization, agile capacity management, resource allocation, and risk mitigation. To help you excel in this ever-changing landscape, we're excited to present a 2-day conference packed with in-depth content, interactive discussions, and valuable networking opportunities at the 25th European Pharma & Biotech Project, Program, and Portfolio Management Conference.

Join us in London, where industry leaders and fellow executives will come together at the nexus of science, business, and operations to advance Biopharma R&D, Business Analytics, and Decision Making. By attending, you'll gain cutting-edge tools, insights, and organizational strategies to enhance your strategic decision-making, optimize portfolio prioritization and resource planning, and foster value and resilience in your organization.

Here's what you can expect at the conference:

- Engage in dynamic, interactive discussions with industry experts and peers.
- Discover innovative solutions and strategies to tackle today's pharma R&D challenges.
- Build lasting connections with fellow executives and thought leaders in the field.
- Gain access to exclusive insights, tools, and best practices to optimize your decision-making process.
- Don't miss this unique opportunity to elevate your pharma R&D management skills and network with key decision-makers. Mark your calendar and join us for this game-changing event that will redefine your approach to project, program, and portfolio management in the biopharma industry.

We look forward to seeing you in London again!
Best regards,


Katy Frolova
Event Organiser

In the Chair



Tom Halliwell


PIPMG Executive Committee Member & Freelance PPM Consultant

The link between PPM maturity and organizational performance is now firmly established and so opportunities to strengthen, enrich and grow our individual and consequently corporate PPM maturity levels are very valuable. This 2-day conference with its industry leading speakers, high-quality content, interactive discussions and networking, provides a significant opportunity to benefit from lessons networked and to help us to progress up the PPM maturity curve both as individuals and as a profession.

As the meeting chair, I would encourage you to make this conference a priority in your schedule and I look forward to meeting you in the great city of London in March!

Best Regards
Tom

Speakers and Panelists



Anna Cyranka

VP Program and Alliance
Management
Alvotech




Bahadır Cakmak

Early Portfolio and Pipeline
Director
Sandoz



Estelle Bernard-Fichet

Associate Director Project
Management
bit.bio



Gurpreet Singh

Vice President, Managing Director
Integrated Safety
IQVIA



Irena Prasilova

CTO Portfolio Director
MSD



Jörn Lenz

Senior Global Portfolio &
Database Manager
medac



Karen Skinner

Chief Project & Portfolio Officer
LifeArc




Keith Rodgers

Chief Executive Officer Nanoforce
Technology Ltd, Strategic Adviser
Ingenii Ltd & Projects Director
Novitius LLC, PIPMG




Leon Kuhlman

Co-Founder and Managing
Director
Grey Swan Management AG



Lukasz Krawczyk

PMO, Site Head
Polpharma Biologics Gdansk



Maya Zergui-Donain

R&D Portfolio Risk Manager
Sanofi



Marianna Esposito

Director, Business Development
Intelligencia AI




Mirjam Foti

Senior Director PMO
Pharming Group



Michael Has

Portfolio Execution Director
MSD



Phil Mallinder

Executive Director Global Project
Management
AstraZeneca



Richard Bayney

President & Founder
Project & Portfolio Value Creation



Ruppen Nalbandian

Associate Director, Portfolio
Strategy & Operations
AstraZeneca



Sandra Hirschberg

Senior Director, Clinical
Development
Bicycle Therapeutics



Silke Rodrigues

Global Portfolio Manager
medac



Stefanie Abt

Director Business Development
& Innovation and Director Project
Management
AET - Alfred E. Tiefenbacher




Tom Halliwell

PIPMG Executive Committee Member &
Freelance PPM Consultant



Tracy Mak

Director of Operations
Evariste



Vincenzo Garzya

Strategic Planning, Operations, Chief of
Staff
AstraZeneca

Agenda

Day1

IMPROVED DECISION MAKING

"Data is the New Gold"

Clive Humby, *British mathematician and data science pioneer*

In the context of leveraging technologies for improved decision-making in drug development, it underscores the importance of collecting, analyzing, and utilizing data to inform and optimize the drug development process. By leveraging state-of-the-art tools and technologies, pharmaceutical companies can gain new insights into the biology of diseases and potential drug targets, accelerate clinical trial design and execution, and ultimately bring new treatments to patients more quickly and efficiently.

7:30

Registration

8:30

KEYNOTE: LISTENING TO THE EXPERTS: HARNESSING THE POWER OF PATIENT PARTICIPATION IN DECISION-MAKING

Patients are the ultimate beneficiaries of medical research and drug development. Involving them in decision-making ensures that the research is aligned with their needs, preferences, and priorities, resulting in interventions that are more relevant and effective for their well-being. Engaging patients directly allows Pharma/Biotech companies to gain deeper insights which can guide the design of trials with more patient-friendly protocols improving compliance and the development of more targeted and effective treatments that address real-world patient challenges.

Karen will share the approach that LifeArc have taken in engaging and involving patients in their decision-making and key considerations and learnings for effective implementation. This includes:

- different mechanisms to engage patients to achieve well-rounded research that considers various perspectives and integrates diverse expertise.
- Investing in generating jargon free materials and educating patients about the research process, scientific concepts, and terminology, so they can provide informed input and feedback.
- ensuring that patient privacy is maintained and that any sensitive information is handled in accordance with ethical and legal standards.
- recognising patients' contributions by providing compensation for their time and expertise, and by acknowledging their role in research publications and presentations.

Patients are experts through their own experiences and recognising them as such is hugely powerful for healthcare advancement.

Karen Skinner, *Chief Project & Portfolio Officer, LifeArc*



5:30pm

NIGHT BEFORE THE EVENT - MEET & GREET

Welcome to our event! We are so honored and grateful to have you with us!

Come and join us for some drinks, where you will be able to do an early bird registration along with some first-hand networking! All the delegates will start arriving and we will all have a chance to get to know one another - the sooner the better. Drinks, conversations, handshakes, smiles, hugs, whether with your old or new friends from the industry - everyone is welcome!

9:00

RESERVED PRESENTATION: DECISION MAKING ANALYSIS

We are in times of change and we see widespread technological advancements across various industries including Health, pharma and MedTech. This offers numerous opportunities but also challenges. The industry is in flux. Key trends that have been emerging like e-records, tele-health, cloud, e-pharmacy and AI need to be operationalized effectively while complying to regulations. Looking particularly at the European Healthcare market several findings can be drawn, highlighting five main challenges that need to be overcome by health organizations. Typically, this entails project work as project and program management can be a success factor with the right methodologies, tools and experts. However, if done wrong it can also lead to significant budget overflows (Black Swan projects). One lever in the toolbox is efficient decision management which can accelerate program execution and avoid straying from time, scope and budget goals. Fast decision-making is crucial for the success of projects and particularly larger programs.

Leon Kuhlman, *Co-Founder and Managing Director, Grey Swan Management AG*

9:30

PANEL DISCUSSION: IMPROVED DECISION MAKING

Pharmaceutical and Biotech managers can leverage technologies for improved decision making in their Project, Program, and Portfolio Management by adopting the different data driven tools and strategies.

Panel will share best practices from different organizations in:

- Data Analytics and Visualization Tools
- Artificial Intelligence (AI) and Machine Learning (ML)
- Cloud-Based Project and Portfolio Management (PPM) Software
- Simulation and Scenario Analysis
- Internet of Things (IoT) and Wearable Devices

Vincenzo Garzya, *Strategic Planning, Operations, Chief of Staff, AstraZeneca*

Lukasz Krawczyk, *PMO, Site Head, Polpharma Biologics Gdansk*

Gurpreet Singh, *Vice President, Managing Director Integrated Safety, IQVIA*

10:00

Networking Break with Exhibit Viewing (coffee, soft drinks and appetizers served)

Day1

DECIDING ON THE RIGHT MIX OF THERAPEUTIC AREAS

"Efforts and courage are not enough without purpose and direction"

John F. Kennedy, 35th U.S. President

When it comes to deciding on the therapeutic areas to focus on, it's important to have a clear understanding of the purpose and goals of the organization, as well as the needs of the patient population. With a clear direction and purpose, decisions about therapeutic areas can be made with confidence and clarity.

10:30 **CASE STUDY:** HOW TO EFFICIENTLY ALIGN YOUR STRATEGY AND OPERATIONS? TRY A CONCEPT CALLED "OBEYA ROOM"

Many companies are struggling to align their strategy to operations. People who manage operations might lack the visibility or feedback loop to strategy.

How to make sure that this would not be your case? You have to set up correct Objectives, make them Measurable through KR and KPIs and have a feedback loop to your Strategic priorities. You have to align in one loop Strategy -> Planning -> Actions -> Performance.

Irena Prasilova, CTO Portfolio Director, **MSD**

Michael Has, Portfolio Execution Director, **MSD**

11:00 **CASE STUDY:** EVALUATING THE PROJECTS FROM THE IDEA PHASE BY USING THE KNOWLEDGE RESOURCES (GENERIC PORTFOLIO MINDSET)

EVALUATING/PREDICTION/UNDERSTANDING OF THE INNOVATOR;

- Product value
- Medical potential
- Product profile
- Ongoing studies
- IP Intelligence

DEFINING THE DETAILS OF THE GENERIC DEVELOPMENT;

- Competition level
- Markets
- Generic pricing
- Decision

Bahadir Cakmak, Director Early Portfolio & Pipeline, **Sandoz**

11:30 **PANEL DISCUSSION:** ORGANIZATIONAL PROCESSES BEHIND DECISION MAKING
Project, Program and Portfolio Management helps biopharma organizations maximize the value of their R&D investments and drive innovation in the most promising therapeutic areas. This panel discussion will address various and most important areas to master to determine the right mix of therapeutic areas including strategically aligning projects, allocating resources, managing risks, monitoring performance, and continuously improving processes.

Silke Rodrigues, Global Portfolio Manager, **medac**

Richard Bayney, President & Founder, **Project & Portfolio Value Creation**

Jörn Lenz, Senior Global Portfolio & Database Manager, **medac**

Anna Cyranka, VP Program and Alliance Management, **Alvotech**

12:00 Lunch Break with Exhibit Viewing

ASSESSING PORTFOLIO RISK

"Drug development is a risky business, but it is an essential one. The ultimate success of our efforts is not always within our control, but our efforts are always under our control."

Freda Lewis-Hall, renowned physician and former Chief Medical Officer of Pfizer

Developing new drugs involves a significant investment of time, money, and resources, and success is never guaranteed. However, despite these challenges, the pursuit of drug development is essential for improving human health and well-being. By focusing on what is within their control, such as rigorous research and development processes and strategic partnerships, pharmaceutical and biotech companies can help mitigate risk and increase the chances of success in this important and challenging field.

13:00 **CASE STUDY:** DRUG DEVELOPMENT: PROCESS, PEOPLE, AND GOVERNANCE
Biotech and pharmaceutical companies are very complex by nature and encounter numerous challenges. How to enhance complex cross-functional collaboration, communication, decision making? Right processes and governance are pivotal to decrease such complexity and to be successful.

Mirjam Foti, Senior Director PMO, **Pharming Group**

13:30 **RESERVED PRESENTATION:** LEVEL UP YOUR STRATEGIC PORTFOLIO DECISION-MAKING WITH AI

AI is here to stay. Will you embrace it to bring your portfolio and asset strategy to the next level? Join us for an interactive session on why AI should be part of your toolkit, how it fits into your organization's workflows, and where it can increase decision-making confidence.

Marianna Esposito, Director, Business Development, **Inteligencia AI**

Day1

14:00 **PANEL DISCUSSION:** OPTIMIZING PORTFOLIO BASED ON RISK AND RETURN ASSESSMENT

In this panel discussions we will explore several approaches that helped biotech and pharma companies to optimize the portfolio: Based on the risk and return assessment, identifying opportunities to optimize the portfolio. This involves adjusting resource allocations, prioritizing, or deprioritizing certain projects, or pursuing new partnerships or collaborations to mitigate risks or enhance returns.

Karen Skinner, Chief Project & Portfolio Officer, **LifeArc**

Phil Mallinder, Executive Director Global Project Management, **AstraZeneca**

Anna Cyranka, VP Program and Alliance Management, **Alvotect**

Bahadir Cakmak, Director Early Portfolio & Pipeline, **Sandoz**

Stefanie Abt, Director Business Development & Innovation and Director Project Management, **AET** - **Alfred E. Tiefenbacher**

14:30 Networking Break with Exhibit Viewing (coffee, soft drinks and appetizers served)

DECISION ANALYSIS AND STRUCTURED DECISION MAKING

"Structured decision-making requires careful analysis of all available information, as well as an understanding of the broader context in which decisions are made."

Rachel King, co-founder and former CEO of **GlycoMimetic**

Making informed decisions requires a careful analysis of all available information, including scientific data, market trends, and patient needs. However, effective decision-making also requires an understanding of the broader context in which decisions are made, including the competitive landscape and regulatory environment. By combining rigorous analysis with a deep understanding of the industry and broader context, biotech companies can make informed decisions that increase their chances of success and ultimately lead to better outcomes for patients.

15:00 **KEYNOTE:** FROM CHAOS TO PROCESSES – HOW TO ORGANIZE BUSINESS DEVELOPMENT

- Identification of the problems during the development as well as lifecycle management of a product
- Implementation of structured processes to improve business development.
- Struggles and opportunities of a decentralized portfolio management environment

Silke Rodrigues, Global Portfolio Manager, **medac**

KEYNOTE: FROM PROCESSES TO TOOLS – IT SOLUTIONS FOR BUSINESS DEVELOPMENT

- Organize data in a process guided tool embedded in an existing IT landscape
- Enable simultaneous collaboration of multidisciplinary teams
- Individual dashboarding and data analysis to improve decision making

Jörn Lenz, Senior Global Portfolio & Database Manager, **medac**

16:00 **KEYNOTE:** CHASING THE LONG RANGE PLAN - A NECESSARY PREOCCUPATION OF PORTFOLIO MANAGEMENT

Richard Bayney, President & Founder, **Project & Portfolio Value Creation**

16:30 **PANEL DISCUSSION:** "THE ART AND SCIENCE OF DECISION-MAKING IN BIOTECH"

This panel discussion will address several approaches of different Pharma and Biotech companies to build a structured decision-making process.

Mirjam Foti, Senior Director PMO, **Pharming Group**

Sandra Hirschberg, Senior Director, Clinical Development, **Bicycle Therapeutics**

Lukasz Krawczyk, PMO, Site Head, **Polpharma Biologics Gdansk**

17:00 **Networking Reception with Exhibit Viewing**

Come and shake off any excess energy from the fruitful and insightful day 1 of the conference and join us for a cocktail hour accompanied by drinks and a great atmosphere to give you a chance to meet the chosen ones you couldn't connect with during the day! We will see each other with drinks in our hands and with all the excitement gathered from our first day!



Day2

GOVERNANCE AND RISK MANAGEMENT

"In the pharmaceutical industry, effective governance and risk management are critical to success. Systems like project management tools, portfolio management software, and risk assessment frameworks can help us manage complex projects and programs and ensure we are making informed decisions based on sound risk analysis."

Leonard Schleifer, CEO and founder of Regeneron Pharmaceuticals

Complex projects and programs in drug development require effective management and oversight to ensure they stay on track and deliver the desired outcomes. Project management tools, portfolio management software, and risk assessment frameworks can help companies manage these challenges and make informed decisions based on sound risk analysis. However, the effectiveness of these systems depends on their implementation, as well as the quality and accuracy of the data used to inform them. By incorporating these systems into their governance and risk management processes, pharmaceutical and biotech companies can increase their chances of success and deliver innovative treatments and therapies to patients in need.

8:30 **KEYNOTE:** PROJECT GOVERNANCE – ROOM FOR IMPROVEMENT?

- What is project governance?
- What are the benefits and challenges of project governance?
- Is there a relationship between project governance and project success?
- Stakeholder-oriented governance of projects

Tom Halliwell, PIPMG Executive Committee Member & Freelance PPM Consultant

9:00 **KEYNOTE:** THE BIOTECH BALANCING ACT: TAKING DECISIONS IN A DYNAMIC ENVIRONMENT

Sandra Hirschberg, Senior Director, Clinical Development, **Bicycle Therapeutics**

9:30 **KEYNOTE:** TO INVEST OR NOT INVEST? WHAT'S THE DECISION?

Phil Mallinder, Executive Director Global Project Management, **AstraZeneca**

10:00 Networking Break with Exhibit Viewing (coffee, soft drinks and appetizers served)

10:30 **PANEL DISCUSSION:** „BUILDING A BIOTECH LEGACY“

In this session an expert panel will discuss the importance of effective governance and risk management in the pharmaceutical industry and highlight the value of using systems such as project management tools, portfolio management software, and risk assessment frameworks to manage complex projects and make informed decisions based on sound risk analysis.

Lukasz Krawczyk, PMO, Site Head, **Polpharma Biologics Gdansk**

Tom Halliwell, PIPMG Executive Committee Member & Freelance PPM Consultant

Tracy Mak, Director of Operations, **Evariste**

11:00 **KEYNOTE:** A JOURNEY TO BOOST RISK CULTURE AND TEAM'S ABILITY TO TAKE SMART RISKS IN THEIR PROJECTS

Improving the risk culture in R&D projects helps teams to transform their mindset and risk-related behaviors as part of project execution.

Boosting thoughtful risk-taking within project teams leads to greater risk mastery and thus maximizes opportunities. Learn about the challenges to be overcome, the stepwise approach adopted, and the solution designed, to instill a risk management culture to foster innovation within R&D. And how to strengthen risk mastery to evolve towards a Portfolio risk-based decision-making.

Maya Zergui-Donain, R&D Portfolio Risk Manager, **Sanofi**

11:30 **KEYNOTE:** PORTFOLIO SIMPLIFICATION - RUMELT'S STRATEGY IN ACTION

During this session the speaker will talk about the journey that led him to downsize the portfolio and execute on Rumelt's strategy to simplify and iteratively prioritize projects.

Vincenzo Garzya, Strategic Planning, Operations, Chief of Staff, **Astrazeneca**

12:00 Lunch Break with Exhibit Viewing

ALIGNING PROJECT AND PROGRAM EXECUTION TO CORPORATE STRATEGY

"Culture eats strategy for breakfast"

Peter Drucker, one of the most widely known and influential thinkers on management

To ensure effective execution of strategy and decision making, Pharmaceutical and Biotech organizations must focus not only on developing a strong strategy but also on cultivating a culture that is supportive of that strategy. This may involve identifying and addressing cultural barriers to change, fostering a sense of ownership and accountability among employees, building continuous improvement, provide strong leadership, transparent performance measurement, regular reviews and incorporate diversity and inclusion across organization.

13:00 **KEYNOTE:** THE EVOLUTION OF PROJECT, PROGRAMME & PORTFOLIO MANAGEMENT – DINOSAURS TO ARTIFICIAL INTELLIGENCE

Keith Rodgers, Chief Executive Officer, **Nanoforce Technology Ltd**, Strategic Adviser, **Inngenii Ltd** & Projects Director, **Novitious LLC**, PIPMG

Day2

13:30 KEYNOTE: AI IN CANCER DIAGNOSTICS: APPLICATIONS, CHALLENGES AND INTEGRATION
Explore the transformative potential of AI in medicine, addressing its uses in enhancing diagnostics, drug discovery, and treatment planning, alongside the challenges and strategies for successful integration in project management.

Ruppen Nalbandian, Associate Director, Portfolio Strategy & Operations, **AstraZeneca**

14:00 PANEL DISCUSSION: AI AND PERSONALIZED MEDICINE
We will learn how our expert panelists are leveraging AI and machine learning to identify patient-specific factors that may impact treatment effectiveness and how this helps PPM managers prioritize projects that focus on the development of targeted therapies, which have a higher likelihood of success and a better return on investment.

Vincenzo Garzya, Strategic Planning, Operations, Chief of Staff, **Astrazeneca**

Tracy Mak, Director of Operations, **Evariste**

Ruppen Nalbandian, Associate Director, Portfolio Strategy & Operations, **AstraZeneca**

Stefanie Abt, Director Business Development & Innovation and Director Project Management, **AET**
- **Alfred E. Tiefenbacher**

14:30 Networking Break with Exhibit Viewing (coffee, soft drinks and appetizers served)

15:00 PANEL DISCUSSION: INCORPORATING DIVERSITY AND INCLUSION ACROSS ORGANIZATION

Mirjam Foti, Senior Director PMO, **Pharming Group**

Karen Skinner, Chief Project & Portfolio Officer, **LifeArc**

Irena Prasilova, CTO Portfolio Director, **MSD**

Lukasz Krawczyk, PMO, Site Head, **Polpharma Biologics Gdansk**

15:30 Q&A WITH THE DAY 1 AND DAY 2 SPEAKERS - JOIN US FOR THE BEST NETWORKING!

16:30 THAT'S A WRAP and END OF THE CONFERENCE!

2024 PPM Summits Worldwide

- 1** March 7 - 8, London, United Kingdom
25th European Pharma and Biotech Project, Program and Portfolio Management Conference
- 2** March 20 - 21, Munich, Germany
2nd Global Project Management, Portfolio Planning and Partnerships for Generics
- 3** April 11 - 12, Chicago, IL, United States
American Medical Device Project & Portfolio Management Conference
- 4** April 18 - 19, Philadelphia, PA, United States
21st American Pharma and Biotech Project, Program and Portfolio Management Conference
- 5** May 22 - 24, Basel, Switzerland
Portfolio Conference – Basel
- 6** June 6 - 7 San Francisco, CA, United States
22nd American Pharma and Biotech Project, Program and Portfolio Management Conference
- 7** September 11 - 12 Mumbai, India
2nd Strategic Project, Program and Portfolio Management Conference for Pharmaceuticals
- 8** September 19 - 20 Barcelona, Spain
3rd Global Project Management, Portfolio Planning and Partnerships for Generics
- 9** October 2 - 3, London, United Kingdom
26th European Pharma and Biotech Project, Program and Portfolio Management Conference
- 10** October 10 -11, Berlin, Germany
2nd European Medical Device Project & Portfolio Management Conference
- 11** October 16 - 18 Boston, MA, United States
23rd American Pharma And Biotech Project, Program And Portfolio Management Conference
- 12** November 20 - 22, Basel, Switzerland
27th European Pharma And Biotech Project, Program And Portfolio Management Conference
- 13** November 13 - 15, Las Vegas, NV, United States
Portfolio Conference – Las Vegas

Sponsorship



Additional sponsorship opportunities are available for those who wish to further customize their involvement.

Exhibiting

With a large and senior audience and decision makers, thoroughly selected, exhibiting at any Summit at 2023 PPM SUMMIT WORLD is a popular sponsorship option with great value for solution providers.

Sponsorship includes:

- Selected Summit Three Access Passes
- Exhibition space
- Helping to prearrange face to face meetings with selected participants

Dinner Sponsorship

2023 PPM SUMMIT WORLD TOUR will host a series of dinners. These dinners bring together thoughtfully selected groups of 15-20 peers from established pharma, biotech, healthcare, and medtech companies. The dines start with a 30 minute networking reception followed by a 60 minute seated dinner, with the option for participants to remain afterward to continue networking.

- Selected Summit Three Access Passes
- 30-minute reception, and 60 minute seated dinner

Speaking

Limited speaking opportunities are available for our sponsoring partners to demonstrate the expertise of their organization. Be sure to ask about these early so we can ensure your presentation flows seamlessly with the overall content. Speaking sponsorships has several options – keynote presentations, case study presentations, expert presentations, panel discussions, workshops or roundtable leadership. Speaking opportunities are available for experts in the field of Project and Portfolio Management, Contract Management, Consultancy, CMO, CRO, Data Management and Intelligence, Artificial Intelligence, Robotics, IoT and Digital Innovations.

Contact us



SPEAKING:

Katy Frolova

katy.frolova@whysummits.com



ATTENDING AND SPONSORING:

Srihari Kamban

shk@whysummits.com

REGISTER HERE



FROM
2349£

DISCLAIMER

Please note – all of the information in this document is subject to change at any time. Whilst every effort has been made to ensure the accuracy of the information, statements and decisions recorded in them, their status will remain that of a draft until such time as they are confirmed as a final version prior the subsequent meeting. Additionally, the user information is only valid at a certain moment in time and is subject to change due to movement and changes in bit rate requirements.